Teva to expand women's health

According to "Bloomberg", Teva plans for women's health products to reach $460-500 million in 2013.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) will expand its women's health operations, president and CEO Jeremy Levin said at the JPMorgan Chase & Co. healthcare conference in San Francisco earlier this week. “Women’s health in the pharmaceutical industry is always focused on fertility and infertility,” he said, adding that contraception is really important, fertility is important, but there are many other diseases which affect only women. “Nobody has taken leadership; this is where we want to go, he concluded.

According to "Bloomberg", Teva plans for women's health products to reach $460-500 million in 2013, amounting to 6% of its brand products sales. The company produces oral contraceptives and hormone therapies for menopause, but Levin said that it may contemplate treatments for uterine fibroids.

"Bloomberg" notes that most of Teva's focus in women's health in on reproduction. At the annual American Society of Reproductive Medicine meeting in October, Teva published successful late-stage trial results for Milprosa, a weekly progesterone vaginal ring for women undergoing in-vitro fertilization, and for Quartette, an ascending-dose, extended oral contraceptive.

Levin also noted that 70% of Copaxone, Teva's brand treatment for multiple sclerosis, was used by women. "Our understanding of women’s health stems from that,” he said. “It’s a huge opportunity. Women are great consumers of medicines, they understand what it is that they need to make themselves happier and healthier."

Published by Globes [online], Israel business news - www.globes-online.com - on January 10, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס